{"id":921021,"date":"2025-12-18T09:40:27","date_gmt":"2025-12-18T14:40:27","guid":{"rendered":"https:\/\/www.marketnewsdesk.com\/index.php\/biofrontera-inc-completes-transfer-of-ameluz-and-rhodoled-fda-approval-and-associated-intellectual-property-portfolio\/"},"modified":"2025-12-18T09:40:27","modified_gmt":"2025-12-18T14:40:27","slug":"biofrontera-inc-completes-transfer-of-ameluz-and-rhodoled-fda-approval-and-associated-intellectual-property-portfolio","status":"publish","type":"post","link":"https:\/\/www.marketnewsdesk.com\/index.php\/biofrontera-inc-completes-transfer-of-ameluz-and-rhodoled-fda-approval-and-associated-intellectual-property-portfolio\/","title":{"rendered":"Biofrontera Inc. Completes Transfer of Ameluz\u00ae and RhodoLED\u00ae FDA approval and Associated Intellectual Property Portfolio"},"content":{"rendered":"<div class=\"mw_release\">\n<p align=\"justify\">\n        <b>\u2022 Ameluz<\/b><br \/>\n        <sup><br \/>\n          <b>\u00ae<\/b><br \/>\n        <\/sup><br \/>\n        <b> and RhodoLED<\/b><br \/>\n        <sup><br \/>\n          <b>\u00ae<\/b><br \/>\n        <\/sup><br \/>\n        <b> New Drug Application (NDA) and Investigational New Drug Application (IND) have successfully been transferred to Biofrontera Inc.<\/b><br \/>\n        <br \/>\n        <b>\u2022 Assignment to Biofrontera Inc. of 11 granted US patents, 10 pending US patent applications and various trademarks associated with Ameluz<\/b><br \/>\n        <sup><br \/>\n          <b>\u00ae<\/b><br \/>\n        <\/sup><br \/>\n        <b> and the RhodoLED<\/b><br \/>\n        <sup><br \/>\n          <b>\u00ae<\/b><br \/>\n        <\/sup><br \/>\n        <b> Lamp Series has been applied for registration with the relevant authorities, including the US Patent Office (USPTO)<\/b><br \/>\n        <br \/>\n        <b>\u2022 In addition, 19 international patent applications and\/or registered designs for RhodoLED<\/b><br \/>\n        <sup><br \/>\n          <b>\u00ae<\/b><br \/>\n        <\/sup><br \/>\n        <b> lamps outside of the US were acquired and registration of the transfer has been initiated <\/b>\n      <\/p>\n<p align=\"justify\">\n        <strong>WOBURN, Mass., Dec.  18, 2025  (GLOBE NEWSWIRE) &#8212; <\/strong>Biofrontera Inc. (Nasdaq: BFRI) (\u201cBiofrontera\u201d or the \u201cCompany\u201d), a leader in photodynamic therapy (PDT) development and commercialization, today announced the completion of the transfer of the FDA approvals for Ameluz<sup><b>\u00ae<\/b><\/sup> and the RhodoLED<sup>\u00ae<\/sup> Lamp Series, including the NDA and the Investigational New Drug Application (IND), to Biofrontera. In addition, the Company has completed all necessary filings to transfer all US and some international intellectual property associated with Ameluz<sup>\u00ae<\/sup> and the RhodoLED<sup>\u00ae<\/sup> Lamp Series, including 11 granted US patents, 10 US patent applications, and 19 patent filings or registered designs outside of the US. The registration of the assignment to Biofrontera of all associated trademarks has also been initiated. These asset transfers were secured, in part, by an $11.0 million investment recently reported by the Company.<\/p>\n<p align=\"justify\">With the NDA and IND transfers effective as of December 17, 2025, Biofrontera now assumes full control of the Ameluz<sup><b>\u00ae<\/b><\/sup> NDA and IND, enabling the Company to manage ongoing and future clinical development activities independently, and to take full responsibility for all aspects of manufacturing and marketing Ameluz<sup>\u00ae<\/sup> and the RhodoLED<sup>\u00ae<\/sup> lamps in the US. The patent and trademark transfers further strengthen Biofrontera\u2019s intellectual property portfolio and market position in the US.<\/p>\n<p align=\"justify\">\u201cThis achievement represents the next important milestone in the transformative arrangement we initiated in June 2025,\u201d said Dr. Hermann Luebbert, CEO and Chairman of Biofrontera. \u201cBy consolidating control of Ameluz\u2019s US regulatory filings and its robust patent portfolio, we are positioned to drive operational efficiencies, optimize R&amp;D expenditures, swiftly pursue new indications, and continue refining our RhodoLED<sup>\u00ae<\/sup> lamp platform \u2014 to meet and exceed the evolving needs of clinicians and patients.\u201d<\/p>\n<p align=\"justify\">\n        <b>About Biofrontera Inc.<\/b>\n      <\/p>\n<p align=\"justify\">Biofrontera is a U.S.-based biopharmaceutical company specializing in the treatment of dermatological conditions with a focus on PDT. The Company commercializes the drug-device combination Ameluz<sup>\u00ae<\/sup> with the RhodoLED<sup>\u00ae<\/sup> lamp series for PDT of Actinic Keratosis, pre-cancerous skin lesions which may progress to invasive skin cancers<sup>1<\/sup>. The Company performs clinical trials to extend the use of the products to treat non-melanoma skin cancers and moderate to severe acne. For more information, visit\u00a0<a href=\"https:\/\/www.globenewswire.com\/Tracker?data=DiZwJt_jUEGEJ7AmUdSEsI8msnNMTsu6g_52cvBO0yUNZxJru2boKs89hdfsyK4Ts5K9eZVxod3JgzrH409Gy4UBJyWgYGSUQ_gSErjxfSY=\" rel=\"nofollow\" target=\"_blank\">www.biofrontera-us.com<\/a>\u00a0and follow Biofrontera on\u00a0<a href=\"https:\/\/www.globenewswire.com\/Tracker?data=A5I3MtjQmbjSINH1Wq0l75XOL-CEOs94Rr4DH8zis0ptipJEZNldZkMfPDd8_a36qjjKRm-7cDvhGq-8oHnWHh1rbilKVk4i_8MuMq0DAzU-9iM1yHN4KrkRV2iB6AFc\" rel=\"nofollow\" target=\"_blank\">LinkedIn<\/a>\u00a0and\u00a0<a href=\"https:\/\/www.globenewswire.com\/Tracker?data=qw5OIaZLaTQ1mR_Tm3rJh_iPFWaThgviKDHOKao4TSb0cnGqk20vCJBBDqnvS3Ks1jKJmS5b0MJmzXtc8TMHcA==\" rel=\"nofollow\" target=\"_blank\">X<\/a>.<\/p>\n<p>\n        <b>References<\/b><br \/>\n        <br \/>1 <a href=\"https:\/\/www.globenewswire.com\/Tracker?data=wl1GmaNpmzWuVklfZxGlhkYOQoS7zeneZ8p4s06nwlQdHjFSWyryrjSJQ0VA8ENbiNtbvq-duQg5CyM4HZ2HO96LAZEsLtmbRBi21JO0lLHlsjKLZ2E5Gd2E1RB2kd5I-7OGjlwH4RHlb3fQeCjnh6NwhBPsgyu8PgZMvrfRYZFW2Nhs_LzvKZfzJLYQ9Pib3adnfPVLdyfrr80kR2bHK9tg_UNCAqJRHq5Flz5wYN0=\" rel=\"nofollow\" target=\"_blank\">https:\/\/www.skincancer.org\/skin-cancer-information\/actinic-keratosis\/<\/a><\/p>\n<p align=\"justify\">\n        <b>Forward-Looking Statements<\/b>\n      <\/p>\n<p align=\"justify\">Certain statements in this press release may constitute \u201cforward-looking statements\u201d within the meaning of the United States Private Securities Litigation Reform Act of 1995, as amended. These statements include, but are not limited to, statements relating to Biofrontera&#8217;s commercial opportunities and the commercial success of its products. We have based these forward-looking statements on our current expectations and projections about future events. Nevertheless, actual results or events could differ materially from the plans, intentions and expectations disclosed in, or implied by, the forward-looking statements we make. These risks and uncertainties, many of which are beyond our control, include, but are not limited to: the uncertainties inherent in the initiation and conduct of clinical trials; availability and timing of data from clinical trials; whether results of earlier clinical trials or trials of Ameluz<sup>\u00ae\u00a0<\/sup>in combination with BF-RhodoLED<sup><b>\u00ae<\/b><\/sup> and\/or RhodoLED<sup><b>\u00ae<\/b><\/sup> XL in different disease indications or product applications will be indicative of the results of ongoing or future trials; uncertainties associated with regulatory review of clinical trials and applications for marketing approvals; the impact of any extraordinary external events; the Company\u2019s ability to achieve and sustain profitability; whether the current global disruptions in supply chains will impact the Company\u2019s ability to obtain and distribute its products; changes in the practices of healthcare providers, including any changes to the coverage, reimbursement and pricing for procedures using the Company\u2019s products; whether the market opportunity for Ameluz\u00a0<sup>\u00ae\u00a0<\/sup>in combination with BF- RhodoLED<sup><b>\u00ae<\/b><\/sup> and\/or RhodoLED<sup><b>\u00ae<\/b><\/sup> XL is consistent with the Company\u2019s expectations; the Company\u2019s ability to retain and hire key personnel; the sufficiency of cash resources and need for additional financing; and other factors that may be disclosed in the Company\u2019s filings with the Securities and Exchange Commission (the \u201cSEC\u201d), which can be obtained on the SEC\u2019s website at\u00a0<a href=\"https:\/\/www.globenewswire.com\/Tracker?data=EVnhsm6mKpb5VsoaP-mZrVfBaCG-3mVSSmCfwr3dWxOeY8e3VfCjUsZDYfr0xx-STpPc6wfIcT-_GgZ2uLFw5LsZD6RGJfdO8SkJ2qwfyrI4z-hpachkrSQiwOkvgzsxSsSqHH3zkgJf22WSE9sDirQA_thX2akl-pn-SOKc0n5Cli5Hk7pFS0DCAPJVM1A5YCAUIhUTLsGZGYwJAZSJdBBwlXIkEDFFaDE2EkI9pS0=\" rel=\"nofollow\" target=\"_blank\">www.sec.gov<\/a>. Readers are cautioned not to place undue reliance on the forward-looking statements, which speak only as of the date on which they are made and reflect management\u2019s current estimates, projections, expectations and beliefs. The Company does not plan to update any such forward-looking statements and expressly disclaims any duty to update the information contained in this press release except as required by law.<\/p>\n<p align=\"justify\">Investor Relations<br \/>Ben Shamsian<br \/>646-829-9701<br \/><a href=\"https:\/\/www.globenewswire.com\/Tracker?data=rzLrdJDqlw7RyQHrH4AtN2nt6Br1erCmrBZLmk8KEg8q0hXgArc7JWSSFvBD_IUmzdnRxh1AAirvOCzF86u_wqjfZ6G03VBQtfM5f1-Mvitq1Qi9mAKGbZUG6PWkUBAV\" rel=\"nofollow\" target=\"_blank\">shamsian@lythampartners.com<\/a><\/p>\n<p>      <img decoding=\"async\" alt=\"\" class=\"__GNW8366DE3E__IMG\" src=\"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTYwNDQ3MSM3MzI4NjU1IzUwMDA4NTk2Mw==\" \/><br \/>\n      <br \/>\n      <img decoding=\"async\" alt=\"\" src=\"https:\/\/ml.globenewswire.com\/media\/ZmQ5NDQzNzAtOWQ1MS00OTA1LWFlZWItMTk5ZjY4ZjE2ZmQwLTUwMDA4NTk2My0yMDI1LTEyLTE4LWVu\/tiny\/Biofrontera-Inc-.png\" \/>\n    <\/div>\n<div class=\"mw_contactinfo\"><\/div>\n","protected":false},"excerpt":{"rendered":"<p>\u2022 Ameluz \u00ae and RhodoLED \u00ae New Drug Application (NDA) and Investigational New Drug Application (IND) have successfully been transferred to Biofrontera Inc. \u2022 Assignment to Biofrontera Inc. of 11 granted US patents, 10 pending US patent applications and various trademarks associated with Ameluz \u00ae and the RhodoLED \u00ae Lamp Series has been applied for registration with the relevant authorities, including the US Patent Office (USPTO) \u2022 In addition, 19 international patent applications and\/or registered designs for RhodoLED \u00ae lamps outside of the US were acquired and registration of the transfer has been initiated WOBURN, Mass., Dec. 18, 2025 (GLOBE NEWSWIRE) &#8212; Biofrontera Inc. (Nasdaq: BFRI) (\u201cBiofrontera\u201d or the \u201cCompany\u201d), a leader in photodynamic therapy (PDT) development and commercialization, today &hellip; <\/p>\n<p class=\"link-more\"><a href=\"https:\/\/www.marketnewsdesk.com\/index.php\/biofrontera-inc-completes-transfer-of-ameluz-and-rhodoled-fda-approval-and-associated-intellectual-property-portfolio\/\" class=\"more-link\">Continue reading<span class=\"screen-reader-text\"> &#8220;Biofrontera Inc. Completes Transfer of Ameluz\u00ae and RhodoLED\u00ae FDA approval and Associated Intellectual Property Portfolio&#8221;<\/span><\/a><\/p>\n","protected":false},"author":2,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[],"tags":[],"class_list":["post-921021","post","type-post","status-publish","format-standard","hentry"],"yoast_head":"<!-- This site is optimized with the Yoast SEO plugin v28.9 - https:\/\/yoast.com\/product\/yoast-seo-wordpress\/ -->\n<title>Biofrontera Inc. Completes Transfer of Ameluz\u00ae and RhodoLED\u00ae FDA approval and Associated Intellectual Property Portfolio - Market Newsdesk<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/www.marketnewsdesk.com\/index.php\/biofrontera-inc-completes-transfer-of-ameluz-and-rhodoled-fda-approval-and-associated-intellectual-property-portfolio\/\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Biofrontera Inc. Completes Transfer of Ameluz\u00ae and RhodoLED\u00ae FDA approval and Associated Intellectual Property Portfolio - Market Newsdesk\" \/>\n<meta property=\"og:description\" content=\"\u2022 Ameluz \u00ae and RhodoLED \u00ae New Drug Application (NDA) and Investigational New Drug Application (IND) have successfully been transferred to Biofrontera Inc. \u2022 Assignment to Biofrontera Inc. of 11 granted US patents, 10 pending US patent applications and various trademarks associated with Ameluz \u00ae and the RhodoLED \u00ae Lamp Series has been applied for registration with the relevant authorities, including the US Patent Office (USPTO) \u2022 In addition, 19 international patent applications and\/or registered designs for RhodoLED \u00ae lamps outside of the US were acquired and registration of the transfer has been initiated WOBURN, Mass., Dec. 18, 2025 (GLOBE NEWSWIRE) &#8212; Biofrontera Inc. (Nasdaq: BFRI) (\u201cBiofrontera\u201d or the \u201cCompany\u201d), a leader in photodynamic therapy (PDT) development and commercialization, today &hellip; Continue reading &quot;Biofrontera Inc. Completes Transfer of Ameluz\u00ae and RhodoLED\u00ae FDA approval and Associated Intellectual Property Portfolio&quot;\" \/>\n<meta property=\"og:url\" content=\"https:\/\/www.marketnewsdesk.com\/index.php\/biofrontera-inc-completes-transfer-of-ameluz-and-rhodoled-fda-approval-and-associated-intellectual-property-portfolio\/\" \/>\n<meta property=\"og:site_name\" content=\"Market Newsdesk\" \/>\n<meta property=\"article:published_time\" content=\"2025-12-18T14:40:27+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTYwNDQ3MSM3MzI4NjU1IzUwMDA4NTk2Mw==\" \/>\n<meta name=\"author\" content=\"Newsdesk\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Newsdesk\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"4 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/biofrontera-inc-completes-transfer-of-ameluz-and-rhodoled-fda-approval-and-associated-intellectual-property-portfolio\\\/#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/biofrontera-inc-completes-transfer-of-ameluz-and-rhodoled-fda-approval-and-associated-intellectual-property-portfolio\\\/\"},\"author\":{\"name\":\"Newsdesk\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\"},\"headline\":\"Biofrontera Inc. Completes Transfer of Ameluz\u00ae and RhodoLED\u00ae FDA approval and Associated Intellectual Property Portfolio\",\"datePublished\":\"2025-12-18T14:40:27+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/biofrontera-inc-completes-transfer-of-ameluz-and-rhodoled-fda-approval-and-associated-intellectual-property-portfolio\\\/\"},\"wordCount\":841,\"image\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/biofrontera-inc-completes-transfer-of-ameluz-and-rhodoled-fda-approval-and-associated-intellectual-property-portfolio\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=OTYwNDQ3MSM3MzI4NjU1IzUwMDA4NTk2Mw==\",\"inLanguage\":\"en-US\"},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/biofrontera-inc-completes-transfer-of-ameluz-and-rhodoled-fda-approval-and-associated-intellectual-property-portfolio\\\/\",\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/biofrontera-inc-completes-transfer-of-ameluz-and-rhodoled-fda-approval-and-associated-intellectual-property-portfolio\\\/\",\"name\":\"Biofrontera Inc. Completes Transfer of Ameluz\u00ae and RhodoLED\u00ae FDA approval and Associated Intellectual Property Portfolio - Market Newsdesk\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/biofrontera-inc-completes-transfer-of-ameluz-and-rhodoled-fda-approval-and-associated-intellectual-property-portfolio\\\/#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/biofrontera-inc-completes-transfer-of-ameluz-and-rhodoled-fda-approval-and-associated-intellectual-property-portfolio\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=OTYwNDQ3MSM3MzI4NjU1IzUwMDA4NTk2Mw==\",\"datePublished\":\"2025-12-18T14:40:27+00:00\",\"author\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\"},\"breadcrumb\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/biofrontera-inc-completes-transfer-of-ameluz-and-rhodoled-fda-approval-and-associated-intellectual-property-portfolio\\\/#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/biofrontera-inc-completes-transfer-of-ameluz-and-rhodoled-fda-approval-and-associated-intellectual-property-portfolio\\\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/biofrontera-inc-completes-transfer-of-ameluz-and-rhodoled-fda-approval-and-associated-intellectual-property-portfolio\\\/#primaryimage\",\"url\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=OTYwNDQ3MSM3MzI4NjU1IzUwMDA4NTk2Mw==\",\"contentUrl\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=OTYwNDQ3MSM3MzI4NjU1IzUwMDA4NTk2Mw==\"},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/biofrontera-inc-completes-transfer-of-ameluz-and-rhodoled-fda-approval-and-associated-intellectual-property-portfolio\\\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Biofrontera Inc. Completes Transfer of Ameluz\u00ae and RhodoLED\u00ae FDA approval and Associated Intellectual Property Portfolio\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#website\",\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/\",\"name\":\"Market Newsdesk\",\"description\":\"Latest Business News in Real Time\",\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\",\"name\":\"Newsdesk\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"url\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"contentUrl\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"caption\":\"Newsdesk\"},\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/author\\\/newsdesk\\\/\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"Biofrontera Inc. Completes Transfer of Ameluz\u00ae and RhodoLED\u00ae FDA approval and Associated Intellectual Property Portfolio - Market Newsdesk","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/www.marketnewsdesk.com\/index.php\/biofrontera-inc-completes-transfer-of-ameluz-and-rhodoled-fda-approval-and-associated-intellectual-property-portfolio\/","og_locale":"en_US","og_type":"article","og_title":"Biofrontera Inc. Completes Transfer of Ameluz\u00ae and RhodoLED\u00ae FDA approval and Associated Intellectual Property Portfolio - Market Newsdesk","og_description":"\u2022 Ameluz \u00ae and RhodoLED \u00ae New Drug Application (NDA) and Investigational New Drug Application (IND) have successfully been transferred to Biofrontera Inc. \u2022 Assignment to Biofrontera Inc. of 11 granted US patents, 10 pending US patent applications and various trademarks associated with Ameluz \u00ae and the RhodoLED \u00ae Lamp Series has been applied for registration with the relevant authorities, including the US Patent Office (USPTO) \u2022 In addition, 19 international patent applications and\/or registered designs for RhodoLED \u00ae lamps outside of the US were acquired and registration of the transfer has been initiated WOBURN, Mass., Dec. 18, 2025 (GLOBE NEWSWIRE) &#8212; Biofrontera Inc. (Nasdaq: BFRI) (\u201cBiofrontera\u201d or the \u201cCompany\u201d), a leader in photodynamic therapy (PDT) development and commercialization, today &hellip; Continue reading \"Biofrontera Inc. Completes Transfer of Ameluz\u00ae and RhodoLED\u00ae FDA approval and Associated Intellectual Property Portfolio\"","og_url":"https:\/\/www.marketnewsdesk.com\/index.php\/biofrontera-inc-completes-transfer-of-ameluz-and-rhodoled-fda-approval-and-associated-intellectual-property-portfolio\/","og_site_name":"Market Newsdesk","article_published_time":"2025-12-18T14:40:27+00:00","og_image":[{"url":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTYwNDQ3MSM3MzI4NjU1IzUwMDA4NTk2Mw==","type":"","width":"","height":""}],"author":"Newsdesk","twitter_card":"summary_large_image","twitter_misc":{"Written by":"Newsdesk","Est. reading time":"4 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/biofrontera-inc-completes-transfer-of-ameluz-and-rhodoled-fda-approval-and-associated-intellectual-property-portfolio\/#article","isPartOf":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/biofrontera-inc-completes-transfer-of-ameluz-and-rhodoled-fda-approval-and-associated-intellectual-property-portfolio\/"},"author":{"name":"Newsdesk","@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979"},"headline":"Biofrontera Inc. Completes Transfer of Ameluz\u00ae and RhodoLED\u00ae FDA approval and Associated Intellectual Property Portfolio","datePublished":"2025-12-18T14:40:27+00:00","mainEntityOfPage":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/biofrontera-inc-completes-transfer-of-ameluz-and-rhodoled-fda-approval-and-associated-intellectual-property-portfolio\/"},"wordCount":841,"image":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/biofrontera-inc-completes-transfer-of-ameluz-and-rhodoled-fda-approval-and-associated-intellectual-property-portfolio\/#primaryimage"},"thumbnailUrl":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTYwNDQ3MSM3MzI4NjU1IzUwMDA4NTk2Mw==","inLanguage":"en-US"},{"@type":"WebPage","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/biofrontera-inc-completes-transfer-of-ameluz-and-rhodoled-fda-approval-and-associated-intellectual-property-portfolio\/","url":"https:\/\/www.marketnewsdesk.com\/index.php\/biofrontera-inc-completes-transfer-of-ameluz-and-rhodoled-fda-approval-and-associated-intellectual-property-portfolio\/","name":"Biofrontera Inc. Completes Transfer of Ameluz\u00ae and RhodoLED\u00ae FDA approval and Associated Intellectual Property Portfolio - Market Newsdesk","isPartOf":{"@id":"https:\/\/www.marketnewsdesk.com\/#website"},"primaryImageOfPage":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/biofrontera-inc-completes-transfer-of-ameluz-and-rhodoled-fda-approval-and-associated-intellectual-property-portfolio\/#primaryimage"},"image":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/biofrontera-inc-completes-transfer-of-ameluz-and-rhodoled-fda-approval-and-associated-intellectual-property-portfolio\/#primaryimage"},"thumbnailUrl":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTYwNDQ3MSM3MzI4NjU1IzUwMDA4NTk2Mw==","datePublished":"2025-12-18T14:40:27+00:00","author":{"@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979"},"breadcrumb":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/biofrontera-inc-completes-transfer-of-ameluz-and-rhodoled-fda-approval-and-associated-intellectual-property-portfolio\/#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/www.marketnewsdesk.com\/index.php\/biofrontera-inc-completes-transfer-of-ameluz-and-rhodoled-fda-approval-and-associated-intellectual-property-portfolio\/"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/biofrontera-inc-completes-transfer-of-ameluz-and-rhodoled-fda-approval-and-associated-intellectual-property-portfolio\/#primaryimage","url":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTYwNDQ3MSM3MzI4NjU1IzUwMDA4NTk2Mw==","contentUrl":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTYwNDQ3MSM3MzI4NjU1IzUwMDA4NTk2Mw=="},{"@type":"BreadcrumbList","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/biofrontera-inc-completes-transfer-of-ameluz-and-rhodoled-fda-approval-and-associated-intellectual-property-portfolio\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/www.marketnewsdesk.com\/"},{"@type":"ListItem","position":2,"name":"Biofrontera Inc. Completes Transfer of Ameluz\u00ae and RhodoLED\u00ae FDA approval and Associated Intellectual Property Portfolio"}]},{"@type":"WebSite","@id":"https:\/\/www.marketnewsdesk.com\/#website","url":"https:\/\/www.marketnewsdesk.com\/","name":"Market Newsdesk","description":"Latest Business News in Real Time","potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/www.marketnewsdesk.com\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Person","@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979","name":"Newsdesk","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","caption":"Newsdesk"},"url":"https:\/\/www.marketnewsdesk.com\/index.php\/author\/newsdesk\/"}]}},"_links":{"self":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts\/921021","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/users\/2"}],"replies":[{"embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/comments?post=921021"}],"version-history":[{"count":0,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts\/921021\/revisions"}],"wp:attachment":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/media?parent=921021"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/categories?post=921021"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/tags?post=921021"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}